BioNTech produces 10 times more antibodies than Sinovac

People who received BioNTech's coronavirus vaccine had ten times the amount of antibodies than those given China's Sinovac, a Hong Kong study has shown, adding to growing data on different jabs' effectiveness. 

The University of Hong Kong (HKU) research, based on a study of 1,442 healthcare workers, was published in Lancet Microbe on Thursday. However, researchers said antibodies are not the only measure of a vaccine's success at fighting a particular disease.

Tap Here to Add The Daily Star As A Trusted Source

The study adds to the growing body of evidence that vaccines using pioneering mRNA technology -- such as BioNTech and Moderna -- offer better protection against the coronavirus and its variants that those developed by more traditional methods such as using inactivated virus parts.

Epidemiologist Ben Cowling, one of the report's authors, said people should still get vaccinated with Sinovac if there was no other option because some protection was always better than none. 

The researchers said their data suggested "alternative strategies" such as earlier booster shots might be needed to increase protection for those who have received Sinovac.